Impel Pharmaceuticals Inc.

IMPL · NASDAQ
Analyze with AI
12/31/2022
12/31/2021
12/31/2020
12/31/2019
Market Cap$87,919$126,001$197,084$197,084
- Cash$60,654$88,212$7,095$37,001
+ Debt$51,186$29,450$8,411$0
Enterprise Value$78,451$67,239$198,400$160,083
Revenue$12,652$668$0$0
% Growth1,794%
Gross Profit$6,157-$23$0$0
% Margin48.7%-3.4%
EBITDA-$91,276-$70,398-$44,257-$40,844
% Margin-721.4%-10,538.6%
Net Income-$129,440-$76,536-$45,798-$41,859
% Margin-1,023.1%-11,457.5%
EPS Diluted-5.52-5.24-3.49-3.19
% Growth-5.3%-50.1%-9.4%
Operating Cash Flow-$93,642-$66,364-$39,183-$36,487
Capital Expenditures-$1,377-$408-$1,782-$1,523
Free Cash Flow-$95,019-$66,772-$40,965-$38,010
Impel Pharmaceuticals Inc. (IMPL) Financial Statements & Key Stats | AlphaPilot